Vpriv
Named-patient access overview. Vpriv is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Vpriv (velaglucerase alfa) is a recombinant human glucocerebrosidase enzyme replacement therapy approved by the US Food and Drug Administration in February 2010 for long-term enzyme replacement therapy in pediatric and adult patients with Type 1 Gaucher disease. The product is marketed approximately by Takeda following its acquisition of Shire. Velaglucerase alfa is delivered as a 60-minute intravenous infusion every other week at a weight-based dose, typically 60 units per kilogram, though clinical practice individualises the dose.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Vpriv
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Vpriv is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Vpriv in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Vpriv
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.